Niagen Bioscience, Inc. - 8-K Filing
Niagen Bioscience held its 2026 Annual Meeting where stockholders elected directors and voted on two proposals. Directors including Frank L. Jaksch, Jr., Robert Fried, Wendy Yu, Gary Ng, and others received majority 'for' votes; Steven Rubin and Hamed Shahbazi had mixed results. Stockholders ratified Crowe LLP as the independent auditor with 96% approval and approved executive compensation on an advisory basis with 95% support. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $CDXC